GlassScriptPhysician profile
Melin J Narayan
NPI 1710291869
$2,562.55
in general payments reported to CMS, 2019-2025
18 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $228 · 2022: $250 · 2023: $250 · 2024: $431 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $96.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.76 |
| Education | $96.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $249.99 | 2023-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $246.19 | 2024-2025 | Terlivaz |
| Glaxosmithkline, LLC. | $245.72 | 2025 | Benlysta |
| Calliditas Therapeutics US INC. | $183.49 | 2024-2025 | Tarpeyo |
| Genentech USA, INC. | $136.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2023 | Jynarque |
| Alexion Pharmaceuticals, INC. | $125.00 | 2020 | |
| Akebia Therapeutics INC | $125.00 | 2025 | Vafseo |
| Apellis Pharmaceuticals, INC. | $125.00 | 2025 | Empaveli |
| Ardelyx, INC. | $124.83 | 2024 | Xphozah 30 Mg |
| Amgen INC. | $124.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $123.67 | 2024 | |
| Novo Nordisk INC | $111.07 | 2025 | Rivfloza |
| Baxter Healthcare | $104.01 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $103.44 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $96.71 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.80 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melin Narayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.